ST Tiansheng: Summary of 2025 Semi-annual Report
Tiansheng Pharmaceutical Group Co., Ltd. 2025 Semi-annual Report Summary Securities Code: 002872 Securities Abbreviation: ST Tiansheng Announcement Number: 2025-049 Tiansheng Pharmaceutical Group Co., Ltd.
2025 Interim Report Summary
Summary of the 2025 Semi-Annual Report of Tiansheng Pharmaceutical Group Co., Ltd.
1. Important tips
This summary of the semi-annual report comes from the full text of the semi-annual report. In order to fully understand the company's operating results, financial status and future development plans, investors should read the full text of the semi-annual report carefully in the media designated by the China Securities Regulatory Commission.
All directors have attended the board meeting where this report was considered.
Non-standard audit opinion tips
□Applicable Not applicable
The profit distribution plan for the reporting period or the plan for converting public reserve funds into share capital reviewed by the board of directors
□Applicable Not applicable
The company plans not to distribute cash dividends, give away bonus shares, or convert public reserve funds into share capital.
Preferred stock profit distribution plan for the reporting period approved by the board of directors
□Applicable Not applicable
2. Basic situation of the company
- Company profile
Stock abbreviation ST Tiansheng Stock code 002872
Stock Exchange Shenzhen Stock Exchange
Contact and Contact Information Secretary of the Board of Directors Securities Affairs Representative
Name Wang Qin Wang Qin
Office address Chaoyang Industrial Park, Chongqing (Dianjiang Guixi) Chongqing Chaoyang Industrial Park (Dianjiang Guixi) Tel: 023-62910742 023-62910742
Email [email protected] [email protected]
- Main accounting data and financial indicators
Whether the company needs to retroactively adjust or restate previous years’ accounting data
□Yes No
This reporting period is better than the same period last year. This reporting period is better than the same period last year.
increase or decrease
Operating income (yuan) 232,193,701.76 281,424,745.89 -17.49% Net profit attributable to shareholders of listed companies (yuan) -36,712,343.97 -43,108,052.43 14.84% Net profit attributable to shareholders of listed companies excluding non-recurring gains and losses
-40,931,453.85 -47,318,180.62 13.50% profit (yuan)
Net cash flow generated from operating activities (yuan) 25,366,015.11 4,620,420.34 449.00% Basic earnings per share (yuan/share) -0.1154 -0.1356 14.90% diluted earnings per share (yuan/share) -0.1154 -0.1356 14.90% Weighted average return on net assets -1.85% -2.08% 0.23% The end of the reporting period is higher than the end of the reporting period of the previous year.
Final increase or decrease in total assets (yuan) 2,660,074,431.30 2,736,124,198.16 -2.78% Net assets attributable to shareholders of listed companies (yuan) 1,969,806,366.85 2,005,684,070.79 -1.79%
Summary of the 2025 Semi-Annual Report of Tiansheng Pharmaceutical Group Co., Ltd.
- Number of shareholders and shareholding status of the company
Unit: Share
Total number of common shareholders at the end of the reporting period Total number of preferred shareholders with restored voting rights at the end of the reporting period
11,959 0 Number Number (if any)
Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)
Shares held with sales restrictions Pledged, marked or frozen Name of shareholder Nature of shareholder Shareholding ratio Number of shares held
Quantity Share Status Quantity 35,000,00 Pledge
Domestic nature 0 Liu Qun 32.89% 104,590,532 102,961,732
People 11,628,80
Freeze
Chongqing Yudian
state-owned assets
State-owned legal person 4.34% 13,792,255 0 Not applicable 0 Operating group
Ltd.
Nature within the territory
Xia Chongyang 1.55% 4,920,000 0 Not applicable 0 people
Nature within the territory
Zhou Shanqing 1.27% 4,047,750 0 Not applicable 0 people
Nature within the territory
Wu Risheng 1.26% 3,999,404 0 Not applicable 0
people
Tibet Runfu
Air treatment within the country
1.21% 3,833,450 0 Not applicable 0 Engineering technology Legal person
Ltd.
Nature within the territory
Zhou Renyu 0.84% 2,665,100 0 Not applicable 0 people
Nature within the territory
Jiangbo 0.81% 2,586,000 0 Not applicable 0 people
Nature within the territory
Hou Shuqiao 0.72% 2,289,900 0 Not applicable 0 people
Nature within the territory
Jiang Caijuan 0.71% 2,258,300 0 Not applicable 0
people
There is no related relationship between the above-mentioned shareholders or the largest shareholder of the company and other shareholders, nor are they persons acting in concert. The Company is unaware of whether there is a related relationship among other shareholders or whether they are persons acting in concert as stipulated in the "Regulations on the Administration of Acquisitions of Listed Companies".
Shareholders involved in margin trading and securities lending business
Not applicable
Description of the situation (if any)
The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares
□Applicable Not applicable
The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.
□Applicable Not applicable
- Changes in controlling shareholders or actual controllers
Changes in controlling shareholders during the reporting period
□Applicable Not applicable
The company's controlling shareholder did not change during the reporting period.
Changes in actual controller during the reporting period
□Applicable Not applicable
The actual controller of the company did not change during the reporting period.
Summary of the 2025 Semi-Annual Report of Tiansheng Pharmaceutical Group Co., Ltd.
- Table of total number of preferred shareholders of the company and shareholding status of the top 10 preferred shareholders □ Applicable Not applicable
The company has no preference shareholders’ shareholdings during the reporting period.
- Status of bonds existing on the date of approval of the semi-annual report
□Applicable Not applicable
3. Important matters
During the reporting period, there were no major changes in the company's operating conditions. For details, please refer to the full text of the company's "2025 Semi-Annual Report" published on the cninfo.com (http://www.cninfo.com.cn).